Transocean (RIG) beat earnings forecasts and probably has enough cash but Jefferies analyst Eduardo Royes and team still consider its stock to be a bigger risk when compared to its peers (I’m guessing they mean Diamond Offshore Drilling (DO), Noble (NE) and Ensco (ESV), among others). They explain why:
Matthew Lloyd/Bloomberg News
We tweak estimates and raise our PT on lower opex in normalized (as with peers). Liquidity doesn’t look to be an issue in the next few years, but the overhang forTransocean is unchangedwith 16 mostly older UDW floaters uncontracted today and our inability to see enough of an activity ramp to absorb re-entry of these rigs through 2018, downside risk is outsized versus peers. Normalized valuation feels reasonable, but it might give too much credit to UDW activity.
Tough to see the market growing enough to absorb uncontracted rigs. We commendTransocean for figuring out how to materially lower its stacking costs on UDW rigs, and are willing to giveTransocean the benefit of the doubt that reactivation costs for some of these assets may not be significant today. That said, with the floater rigcount likely on pace to fall through YE16 (into the 150-160 range from 190 today), and given the seemingly low likelihood that floater activity in 2017 can do better than stabilize, oversupply conditions simply feel too great to allow for these rigs to come back for years to come (thus calling into question their longer-term economic viability). Although we do not believe there is a material technical disadvantage to Transocean’s older floaters, we suspect the first rigs to secure UDW work as (if) demand starts to emerge will be the currently committed 2013+ deliveries (“6th Gen V 2.0″ rigs), of which many roll off contract in 2017. What’s more, we suspect that more sister units to these 6G V 2.0 rigs will also come into contention for work as (1) better capitalized drillers will likely be willing to take delivery for poor economics initially in order to get work and/or (2) if industry chatter regarding a ramping up in asset transactions does transpire, assets currently not in the hands of financially capable owners will be able to enter the competitive mix.
Top 10 New Companies To Buy Right Now: Huaneng Power International, Inc.(HNP)
Huaneng Power International, Inc., an independent power producer, generates and sells electricity and heat to the regional or provincial grid companies in the Peoples Republic of China and Singapore. It is involved in the development, construction, operation, and management of power plants and related projects; and generation, wholesale, and retail of power and other relating utilities. The company generates power from coal, wind, gas, oil, and hydro resources. In addition, it provides cargo transportation services in coastal areas; warehousing, loading, and conveying services; port management, cargo loading, and water transport material supply; utility services; environment engineering services; consultancy in waste recycling; real estate agency services. Further, the company engages in aquaculture and agriculture irrigation activities; developing and leasing real estate; production and sale of mineral water; port developme nt and construction, coal mixture, and machinery leasing and repair activities; industrial waste management and recycling activities; and the supply of water carriage materials. As of September 1, 2015, it had controlled generating capacity of 81,132 megawatts and a total generating capacity of 72,375 megawatts. The company was founded in 1994 and is headquartered in Beijing, the Peoples Republic of China.
- [By Lisa Levin]
In trading on Friday, utilities shares rose by just 0.5 percent. Meanwhile, top losers in the sector included TransAlta Corporation (USA) (NYSE: TAC), down 1 percent, and Huaneng Power International Inc (ADR) (NYSE: HNP), down 1 percent.
Top 10 New Companies To Buy Right Now: Sohu.com Inc.(SOHU)
Sohu.com Inc. provides online media, search, and game services on personal computers (PCs), mobile devices, and tablets in the Peoples Republic of China. It operates brand advertising business that offers advertisements on its Websites to companies; sohu.com, which provides online news and information; m.sohu.com mobile portal and Sohu News APP, a mobile phone application; tv.sohu.com, which offers online video service; and focus.cn that provides online real estate information. The companys search and search-related business provides Sogou Input Method software to input Chinese characters on PCs and mobile devices; Sogou browser; Sogou Web Directory, a Web directory navigation site for PCs; Sogou Search, a proprietary search engine; and Sogou Browser for PCs and mobile devices, as well as offers pay-for-click services and online marketing services for advertisers. In addition, its online game business offers interactive on line games, mobile games, and Web games for game players. Further, the companys platform channel business owns and operates various Web properties and software applications, including 17173.com, an information portal for game players; RaidCall, which provides online music and entertainment services; and the Dolphin Browser, a gateway to a host of user activities on mobile devices. Additionally, it provides mobile-related services and mobile products; Internet value-added services; and cinema advertising services. The company was formerly known as Internet Technologies China Incorporated and changed its name to Sohu.com Inc. in September 1999. Sohu.com Inc. was founded in 1996 and is headquartered in Beijing, the Peoples Republic of China.
- [By Belinda Cao]
Sohu.com Inc. (SOHU), which sold a stake in its search unit to Tencent Holdings Ltd. (700), advanced 11 percent for the week to $72.06. It retreated 5.9 percent Sept. 20. Tencent, Chinas biggest Internet company by market value, paid $448 million for a 36.5 percent stake in Sohus Sogou unit last week and merge its own search service with Sogou.
10 Best Semiconductor Stocks To Invest In Right Now: Myriad Genetics, Inc.(MYGN)
Myriad Genetics, Inc. (Myriad), incorporated on November 6, 1992, is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Myriad offers diagnostic tests for a range of dise ases, such as Myriad myRisk Hereditary Cancer test for hereditary breast cancer, hereditary ovarian cancer, hereditary pancreatic cancer, hereditary uterine (endometrial) cancer and hereditary colon cancer; Myriad myPlan Lung Cancer test for lung cancer; Myriad myPath Melanoma test for melanoma; Prolaris test for prostate cancer, and Vectra DA for rheumatoid arthritis (RA).
Molecular Diagnostic Testing
The Company’s molecular diagnostic tests are designed to analyze genes, their expression levels and corresponding proteins. Myriad’s primary molecular diagnostic tests include myRisk Hereditary Cancer, a deoxyribonucleic acid (DNA) sequencing test for assessing the risks for hereditary cancers, such as breast cancer, ovarian cancer, colon cancer, uterine cancer, melanoma, pancreatic cancer, prostate cancer and gastric cancer; BRACAnalysis, a DNA sequencing test for assessing the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx ! , a DNA sequencing test for use as a companion diagnostic with the poly (ADP-ribose) polymerase (PARP) inhibitor LynparzaTM (olaparib); Tumor BRACAnalysis CDx, a DNA sequencing test designed to be utilized to predict response to DNA damaging agents, such as platinum-based chemotherapy agents and PARP inhibitors; COLARIS, a DNA sequencing test for assessing the risk of colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for assessing the risk of colorectal cancer; Vectra DA, a protein detection test for assessing the disease activity of rheumatoid arthritis; Prolaris, a ribonucleic acid (RNA) expression test for assessing the aggressiveness of prostate cancer; EndoPredict, an RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, an RNA expression test for diagnosing melanoma, and myPlan Lung Cancer, an RNA expression test for assessing the aggressiveness of lung cancer.
Pharmaceutical and Clinical Services
The Company provides a range of pharmaceutical and clinical services. Through its subsidiary, Myriad RBM, Inc., Myriad provides biomarker discovery and pharmaceutical and clinical services to the pharmaceutical, biotechnology and medical research industries utilizing its multiplexed immunoassay technology. The Company also owns Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG, located approximately 15 miles from the Company’s European laboratories in Munich, Germany. The Company’s technology enables it to screen sets of well-characterized clinical samples from both diseased and non-diseased populations against its menu of biomarkers.
- [By Ben Levisohn]
We took in Walt Disney (DIS) earnings, Argus’ downgrade of Noble (NE), and Myriad Genetics’ (MYGN) freefall.
We looked at the speculation that International Paper (IP) could be a takeover target, and the progress made at Ralph Lauren (RL), and the slowing same-store sales at Shake Shack (SHAK).
Top 10 New Companies To Buy Right Now: Continental Resources, Inc.(CLR)
Continental Resources, Inc., incorporated on November 16, 1967, is an independent crude oil and natural gas exploration and production company with properties in the North, South and East regions of the United States. The North region consists of properties north of Kansas and west of the Mississippi River and includes North Dakota Bakken, Montana Bakken and the Red River units. The South region includes Kansas and all properties south of Kansas and west of the Mississippi River, including various plays in the South Central Oklahoma Oil Province (SCOOP), Sooner Trend Anadarko Canadian Kingfisher (STACK), Northwest Cana and Arkoma Woodford areas of Oklahoma. The East region includes undeveloped leasehold acreage east of the Mississippi River. The Company’s estimated proved reserves are approximately 1,230 million barrels of crude oil equivalent (MMBoe) with estimated proved developed reserves of over 520 MMBoe. Its crude oil production is sold to crude oil refining companie s at market centers.
The Company’s principal producing properties in the North region are in the Bakken field and the Red River units. Its average daily production from such properties is approximately 148,910 Boe per day. The Bakken field of North Dakota and Montana is a crude oil resource play in the United States. The Company is a producer, leasehold owner and operator in the Bakken. Its total Bakken production is over 136,350 Boe per day. It has completed approximately 650 gross wells in the Bakken. Its total proved Bakken field reserves is over 660 MMBoe. It operates approximately eight rigs in the Bakken, all in North Dakota.
The Company’s Red River units consists of over nine units located along the Cedar Creek Anticline in North Dakota, South Dakota and Montana that produce crude oil and natural gas from the Red River B formation. The Company’s principal producing properties in the Red River units include the Cedar Hills units in North Dakota and Montana, the Medicine Pole H! ills units in North Dakota and the Buffalo Red River units in South Dakota. Its properties in the Red River units comprise a portion of the Cedar Hills field.
The Company’s principal producing properties in the South region are located in the SCOOP, Northwest Cana and STACK areas of Oklahoma. Its average daily production from such properties is approximately 76,020 Boe per day. The Company’s SCOOP play extends across Garvin, Grady, Stephens, Carter, McClain and Love counties in Oklahoma, and contains crude oil and condensate-rich fairways as delineated by various industry wells. It is a producer, leasehold owner and operator in the SCOOP play. It has completed over 200 gross wells in SCOOP. The Company’s Northwest Cana properties are located in northwestern Oklahoma in Blaine, Dewey and Custer Counties of Oklahoma and target the Woodford formation. It has approximately five operated rigs drilling in Northwest Cana. It has over four oper ated rigs drilling in STACK. It has completed a combined of approximately 30 gross wells in Northwest Cana and STACK. It has proved reserves of approximately 80 MMBoe.
- [By Ben Levisohn]
The large cap E&Ps we cover raised ~ $6.5 billion of equity in 2015 and are likely to consider additional issuance in 2016. Pioneer Natural Resources (PXD) raised $1.3 billion on January 5th and Hess Corp. (HES) raised $1.5 billion of equity/equity-linked earlier this month. We think highly leveraged companies such as Devon Energy,Encana andRange Resources (RRC) and companies with a large deficit (before asset sales), such asAnadarko Petroleum and Devon Energy, are most likely to consider raising equity. Additionally, we believe companies such as WPX Energy (WPX), Southwestern Energy (SWN), Marathon Oil, Continental Resources (CLR),Noble Energy and Newfield Exploration (NFX) could issue equity while several levered companies may be unwilling or unable to access equity markets. We do not think Apache, Canadian Natural Resource, EOG Resources (EOG), Occidental Petroleum orPioneer Natural Resources are likely to issue equity this year.
Top 10 New Companies To Buy Right Now: Mercury Systems Inc(MRCY)
Mercury Systems, Inc., incorporated on July 14, 1981, is a commercial provider of secure processing subsystems designed and made in the United States. The Company’s solutions support a range of defense and intelligence programs. The Company’s technologies include embedded processing modules and subsystems, radio frequency (RF) and microwave multi-function assemblies, as well as subsystems, and RF and microwave components. In addition, the Company designs and builds RF and microwave components and subsystems to meet the needs of the electronic warfare (EW), signals intelligence (SIGINT) and other high bandwidth communications requirements and applications.
The Company’s programs include Aegis, Patriot, Surface Electronic Warfare Improvement Program (SEWIP), Gorgon Stare, Predator, F-35 and Reaper. The Company provides solutions relating to pre-integrated, open, affordable EW, electronic attack (EA) and electronic counter measure (ECM) subsystems, SIGINT and ele ctro-optical/infrared (EO/IR) processing technologies, and radar environment test and simulation systems. The Company deploys these solutions on behalf of the Department of Defense (DoD). The Company designs and builds integrated sensor processing subsystems, including classified application-specific software and intellectual property (IP) for the command, control, communications, computers, intelligence, surveillance and reconnaissance (C4ISR), EW and ECM markets.
The Company offers analyst services and systems engineering support, consulting, maintenance and other support, testing and installation. The Company designs, markets and sells software and middleware environments for the development and execution of signal and image processing applications on a range of heterogeneous and multi-computing platforms. The Company’s software suite is based on open standards and includes heterogeneous processor support. The Company’s software and middleware provides custom er application-level algorithm portability across a range of! hardware processor types with math and input/output (I/O) interfaces. Its multi-computer software packages are marketed and licensed under the MultiCore Plus brand.
The Company offers products designed to meet a range of requirements in compute-intensive, signal processing and image-processing applications, multi-computer interconnect fabrics, sensor interfaces and command and control functions. The Company offers hardware products into the categories, such as signal and image processing, multi-computer and sensor interfaces, including embedded processing boards, switch fabric boards, digital receiver boards, high-density memory modules, secure solid-state drives, secure global positioning system (GPS) receiver modules, and chassis-based systems using air, conduction, and cooling technologies; RF and microwave assemblies, including tuners, converters, transceivers, and switch filters, and RF and microwave components, including power amplifiers and limiters, swi tches, oscillators, and equalizers. Its open architecture is carried throughout its entire Ensemble product line. In the defense market, its hardware products include anti-tamper and information assurance products, such as EnforcIT, WhiteboxCRYPTO and CodeSEAL. In the commercial market, its hardware products include its CANGuard product, which provides security for the electronic communications and control architectures on a range of automotive vehicles.
- [By Lisa Levin]
Mercury Systems Inc (NASDAQ: MRCY) shares shot up 15 percent to $18.94 after the company agreed to acquire the embedded security, RF and Microwave and custom microelectronics businesses of Microsemi Corporation (NASDAQ: MSCC).
- [By Lisa Levin]
Mercury Systems Inc (NASDAQ: MRCY) shares shot up 15 percent to $19.00 after the company agreed to acquire the embedded security, RF and Microwave and custom microelectronics businesses of Microsemi Corporation (NASDAQ: MSCC).
Top 10 New Companies To Buy Right Now: Heartware International, Inc.(HTWR)
Heartware International, Inc., incorporated on June 29, 2008, is a medical device company. The Company develops and manufactures miniaturized implantable heart pumps or ventricular assist devices to treat patients suffering from advanced heart failure. The Company operates in the segment of design and manufacture of medical devices. The HeartWare Ventricular Assist System (HVAD System), which includes a ventricular assist device (VAD) or blood pump, patient accessories and surgical tools, provides circulatory support for patients in the advanced stage of heart failure. The HVAD System is designed to be implanted adjacent to the heart, avoiding abdominal surgery. The HVAD System features the centrifugal pump designed to be implanted in the chest, directly adjacent to the heart.
The HeartWare HVAD System
The HVAD System consists of HVAD pump, a permanently implantable VAD, patient accessories and surgical tools. The HVAD pump is capable of generatin g over 10 liters of blood flow per minute. With a displaced volume of approximately 50 cubic centimeters and a mass of over 140 grams, the HVAD pump is implantable in the pericardial space, directly adjacent to the heart. The pump’s inflow cannula is integrated with the device itself, providing proximity between the heart and the pumping mechanism, facilitating ease of implant and helping to ensure optimal blood flow characteristics. The use of a wide-bladed impeller and the clear flow paths through the pump are designed to help reduce the risk of pump-induced damage to blood cells.
The HeartWare MVAD System
The MVAD System consists of similar components, surgical tools and peripherals, as the HVAD System, but is differentiated by the MVAD pump. The MVAD pump is a miniaturized blood pump intended for patients with chronic heart failure. The device is a full-output axial-flow pump with a fully suspended rotor and a displacement volume of less than on e-half of that of the HVAD pump.
The CircuLite ! System
The CircuLite Surgical System is designed to be implanted through a right, mini-thoracotomy procedure and does not require a sternotomy or cardiopulmonary bypass. The CircuLite Circulatory Support System offers interventional options to earlier-stage heart failure patients.
The Company competes with St. Jude Medical, Inc., Jarvik Heart, Inc., ReliantHeart Inc., Berlin Heart GmbH and Sunshine Heart, Inc.
- [By Spencer Israel]
4. HeartWare International Inc (NASDAQ: HTWR) – The heart device maker agreed to be acquired by Medtronic for $58 per share in cash two weeks ago. Prior to that the stock had been trading just above $30.
Top 10 New Companies To Buy Right Now: Canadian National Railway Company(CNI)
Canadian National Railway Company, together with its subsidiaries, engages in the rail and related transportation business in North America. It provides transportation for various goods, including petroleum and chemicals, grain and fertilizers, coal, metals and minerals, forest products, and intermodal and automotive products. The company operates a network of approximately 20,600 route miles of track that spans Canada and mid-America, from the Atlantic and Pacific oceans to the Gulf of Mexico. It serves the ports of Vancouver, Prince Rupert (British Columbia), Montreal, Halifax, New Orleans, and Mobile (Alabama), as well as metropolitan areas of Toronto, Buffalo, Chicago, Detroit, Duluth (Minnesota)/Superior (Wisconsin), Green Bay (Wisconsin), Minneapolis/St. Paul, Memphis, and Jackson (Mississippi), with connections to various points in North America. The company was founded in 1922 and is headquartered in Montreal, Canada.
- [By Monica Gerson]
Canadian National Railway (USA) (NYSE: CNI) is estimated to post its quarterly earnings at $0.92 per share on revenue of $3.08 billion.
Container Store Group Inc (NYSE: TCS) is expected to post its quarterly earnings at $0.21 per share on revenue of $230.53 million.
Top 10 New Companies To Buy Right Now: AVG Technologies N.V.(AVG)
AVG Technologies N.V., incorporated on March 3, 2011, provides software and online services. The Company operates through two segments: Consumer and small and medium sized business (SMB). The Consumer segment reflects all direct (subscription) and indirect (platform) revenues targeted at the Consumer segment and including the Location Labs business, and Privax entity. The SMB segment reflects all direct (subscription) revenue targeted at the SMB segment and includes the revenue from the Norman Safeground AS. Its product portfolio includes AVG Anti-Virus FREE, AVG Anti-Virus, AVG Internet Security, AVG Protection FREE suite, AVG Protection PRO suite, AVG Performance suite, AVG Ultimate suite, Anti-Virus Security-FREE, AVG Zen, Mobile Anti-Virus Security-PRO, AVG CleanerMobile Booster & Battery Saver, Gallery, Gallery Doctor, AVG Anti-Virus for Mac, TuneUp Utilities and AVG PC Tuneup, AVG Cleaner for Mac, AVG Driver Updater, AVG Web TuneUp, Alarm Clock Xtreme FREE + Timer , AVG Cleaner-Xperia and HideMyPhone, among others. Its location labs mobile solutions include AT&T FamilyMap, AT&T Smart Limits, Sprint Family Locator, Sprint Mobile Controls, Sprint Drive First, T-Mobile FamilyWhere, Verizon FamilyBase, Safely Go and Aqui Estoy.
The Company’s SMB security platform, AVG CloudCare, enables information technology (IT) management by allowing cloud services and devices to be remotely managed from any Web browser or Android and iPhone operating system (iOS) mobile device applications. IT providers can manage multiple customers from a single cloud dashboard, activate services with a single click, generate a variety of reports, view real-time alerts to problems, and drag and drop documents to create centralized policies. Its AVG CloudCare Products include AVG Remote IT, AVG Anti-Virus, AVG Content Filtering, AVG Cloud Backup and AVG Email Security. Its Norman solutions include Norman Antivirus, Norman Security Suite, Norman Security S uite PRO, Norman Endpoint Protection, Norman Email Protectio! n, Norman Security Portal, Norman SecureMail and Norman SecureSurf. Its product portfolio targets the consumer and SMB markets across multiple devices and operating systems and includes Internet security, personal computer (PC) performance optimization, online backup, identity protection, family safety, mobile control and location services, dynamic secure search, remote control, network auditing, monitoring and alerting software. Its product portfolio also includes virtual private network services.
The Company’s solutions, encompassing software and online services, include security, PC optimization, online privacy, cloud-based desktop management, mobile security, management and location services, content filtering, remote monitoring and other products on various desktop and mobile operating systems. Its software products are available in various languages; used in multiple countries across the world, and sold under software license agreements. They are generally sold and downloaded over the Internet or sold as packaged products through multi-tiered distribution channels. The Company offers AVG Zen, a connected solution across both mobile and PC platforms in order to support expansion into mobile. Through its AVG Business Solutions, the Company offers both security and cloud-based remote monitoring and IT management, and the Company offers both license subscription-based and software-as-a-service (SaaS)-based (monthly) billing. The Company also distributes through resellers and distributors, which the Company refers to as its reseller network.
The Company competes with Avast!, Avira, Symantec, Carbonite, Dropbox, Intel Corporation, Trend Micro, Eset, Kaspersky Labs, Panda Software, Sophos, Bit Defender, Rising, Kingsoft, Check Point, Qihoo, F-Secure, Private Internet Access, Anchor Free, Tunnelbear, UniBlue, Piriform, Kaseya, Solarwinds, Cheetah Mobile, NQ Mobile, Lookout, CM security, Microsoft, Google, Apple, Tencent, Facebook, Lifelock and Life 360.
- [By Igor Novgorodtsev]
InterActiveCorp (IACI) bought Ask.com for $1.85 billion in 2005. The new Perion will be worth only about 40% of that. After the merger, Perion will leapfrog its much larger rivals: Babylon and AVG (AVG). Finally, Perion should be able to increase its operating margins as it can spread its SG&A costs over a much larger base (Conduit EBITDA margin is 32% vs. Perion’s 23%). Perion will keep its senior management team intact: Josef Mandelbaum will remain its CEO and Yacov Kaufman its CFO. Perion has successfully orchestrated a roll-up acquisitions of privately-held Sweetpacks and Smilebox, so I have high confidence that they know how to integrate a new business.
Top 10 New Companies To Buy Right Now: Progenics Pharmaceuticals Inc.(PGNX)
Progenics Pharmaceuticals, Inc., incorporated on December 1, 1986, is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases. The Company’s EXINI Bone BSI is an analytical tool that employs an artificial intelligence-based approach to apply techniques of statistical analysis and pattern recognition to quantify the information produced by bone scintigraphy (bone scan) images used to view cancer present in the skeleton. The EXINI Bone BSI tool reads bone scans and produces a standard, automated Bone Scan Index quantification. The Company’s clinical-stage products include AZEDRA, 1404 (trofolastat), PyL ((18F) DCFPyL), 1095 and PSMA ADC. The Company’s partnered products include Relistor- Subcutaneous injection, Relistor- Oral Tablets and PRO 140.
Azedra is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands. The Company has completed enrollment in pivotal Phase IIb clinical trial under Special Protocol Assessment (SPA).
The Company’s 1404 (trofolastat) is a technetium-99m labeled small molecule, which binds prostate specific membrane antigen (PSMA) and is used as an imaging agent to diagnose and detect localized prostate cancer, as well as soft tissue and bone metastases. The Company has completed a global multi-centered Phase II study assessing the diagnostic accuracy of 1404 imaging in men with high-risk prostate cancer and initiated a multi-center, open-label Phase III trial to determine the sensitivity and specificity of 1404 to correctly identify whether or not patients hav e clinically prostate cancer
PyL ((18F) DCFPyL)!
The Company’s PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer that was discovered and developed at the Center for Translational Molecular Imaging at the Johns Hopkins University School of Medicine. The Company’s studies show the uptake of PyL is high in sites of putative metastatic lesions and primary tumors, suggesting the potential for high sensitivity in detecting prostate cancer.
The Company’s 1095 is a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule, which is designed to deliver a dose of radiation directly to prostate cancer cells with minimal impact on the surrounding healthy tissues. The Company focuses on initiating a Phase I clinical study.
PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer. The Company’s Phase II, multicenter clinical tr ial to assess the safety, tolerability and anti-tumor activity of PSMA ADC, has been completed in both the chemotherapy refractory and chemotherapy naive patients with metastatic castration-resistant prostate cancer (mCRPC).
The Company’s Relistor is used as a treatment for Opioid-Induced Constipation (OIC), which decreases the constipating side effects induced by opioid pain medications, such as morphine and codeine without diminishing their ability to relieve pain. Relistor-Subcutaneous injection is engaged in the treatment of OIC in patients with non-cancer pain, and is marketed in the United States. Relistor-Oral has completed Phase III clinical trials.
The Company’s PRO 140 is a humanized IgG4 monoclonal antibody directed against C-C chemokine receptor type 5 (CCR5), a molecular portal that human immunodeficiency virus (HIV) uses to enter T-cells. PRO 140 blocks the predominant HIV subtype (R5) entry i nto T-cells by masking this required co-receptor, CCR5. PRO ! 140 has b! een the subject of over seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects.
The Company competes with Merck & Co., Inc., Sucampo Pharmaceuticals, Inc., Shionogi & Co., Theravance, Inc., Johnson & Johnson, Medivation, Inc., Bayer HealthCare Pharmaceuticals Inc. and Aytu Bioscience Inc.
- [By Lisa Levin]
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) shares shot up 29 percent to $6.37 after announcing the FDA approval of RELISTOR tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.
Top 10 New Companies To Buy Right Now: Extra Space Storage Inc(EXR)
Extra Space Storage, Inc. operates as a real estate investment trust (REIT) in the United States. It engages in property management and development activities that include acquiring, managing, developing, and selling, as well as the rental of self-storage facilities. As of December 31, 2006, Extra Space Storage owned interests in 567 properties located in 32 states and Washington, D.C., as well as managed 74 properties owned by franchisees or third parties. As a REIT, the company would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 1977 and is based in Salt Lake City, Utah.
- [By Shauna O’Brien]
On Tuesday, Goldman Sachs announced that it has removed Extra Space Storage, Inc. (EXR) from its Conviction Buy List.
The firm has maintained a “Buy” rating on EXR, and has lowered the company’s price target from $51 to $50. This price target suggests a 12% upside from the stock’s current price of $43.94.
Analyst Andrew Rosivach commented: “We think the stock is inexpensive on forward 2018E AFFO, but the higher 2014E multiple may require the stock to consolidate.”
Extra Space Storage shares were down 21 cents, or 0.47%, during Tuesday morning trading. The stock is up 21% YTD.